Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a chronic, debilitating, fibrotic lung disease leading to respiratory failure, and ultimately to death. It is characterized by marked heterogeneity regarding its clinical course. Despite significant progress in the understanding of its pathogenesis, the course of the disease and the response to treatment of an individual patient cannot be reliably predicted today. Areas covered: Non-invasive biomarkers, in particular serum biomarkers, for the (early) diagnosis, differential diagnosis, prognosis, and prediction of therapeutic response are described. The molecules are classified according to their involvement into alveolar epithelial cell injury, fibroproliferation, and matrix remodeling as well as immune regulation. Furthermore, genetic variants of TOLLIP, MUC-5B, and other genes associated with a differential response to treatment and with the development and/or the prognosis of IPF are reported. Expert commentary: The combination of multiple biomarkers may identify comprehensive biomarker signatures in IPF patients. This is a way to apply personalized medicine approach to patient affected by IPF in order to not only improve our ability to diagnose and treat disease but also offer the potential to detect disease at an earlier stage, when it is potentially easier to treat effectively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765 · cited 1×
“The clinical course of IPF is variable, ranging from slow progression over many years to acute exacerbation or rapid loss of lung function; it is associated with considerable comorbidity [109].”
BackgroundTelomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357 · cited 1×
“TERT and TERC mutations have been reported among families with pulmonary fibrosis [62].”
BackgroundDiagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper
Lynch, D. A., Sverzellati, N., Travis, W. D., Brown, K. K., Colby, T. V., Galvin, J. R., Goldin, J. G., Hansell, D. M., Inoue, Y., Johkoh, T., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30433-2 · Cited by 1,030
Self-citationBarry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010) · Nature Medicine · doi:10.1038/nm.2208 · Cited by 870
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
Fingerlin, T. E., Murphy, E., Zhang, W., Peljto, A. L., Brown, K. K., Steele, M. P., Loyd, J. E., Cosgrove, G. P., Lynch, D., Groshong, S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2609 · Cited by 809
Short telomeres are a risk factor for idiopathic pulmonary fibrosis
Alder, J. K., Chen, J. J.-L., Lancaster, L., Danoff, S., Su, S.-C., Cogan, J. D., Vulto, I., Xie, M., Qi, X., Tuder, R. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804280105 · Cited by 805 · cited 1×
“Alveolar epithelial cells and leukocytes from IPF patients have shorter telomeres, as compared with healthy agematched controls [61].”
BackgroundTelomere Shortening in Familial and Sporadic Pulmonary Fibrosis
Cronkhite, J. T., Xing, C., Raghu, G., Chin, K. M., Torres, F., Rosenblatt, R. L., & Kim Garcia, C. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200804-550oc · Cited by 573 · cited 1×
“Moreover, 25% of sporadic cases and 37% of familial cases of pulmonary fibrosis had telomere lengths less than the 10th percentile [70].”
BackgroundStuart, B. D., Choi, J., Zaidi, S., Xing, C., Holohan, B., Chen, R., Choi, M., Dharwadkar, P., Torres, F., Girod, C. E., et al. (2015) · Nature Genetics · doi:10.1038/ng.3278 · Cited by 469
Telomere dysfunction and tumour suppression: the senescence connection
Deng, Y., Chan, S. S., & Chang, S. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2393 · Cited by 411
Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive
Newton, C. A., Batra, K., Torrealba, J., Kozlitina, J., Glazer, C. S., Aravena, C., Meyer, K., Raghu, G., Collard, H. R., & Garcia, C. K. (2016) · European Respiratory Journal · doi:10.1183/13993003.00308-2016 · Cited by 400
Cited by
Inoue, Y., Kaner, R. J., Guiot, J., Maher, T. M., Tomassetti, S., Moiseev, S., Kuwana, M., & Brown, K. K. (2020) · Chest · doi:10.1016/j.chest.2020.03.037 · Cited by 133
Biomarker signatures for progressive idiopathic pulmonary fibrosis
Clynick, B., Corte, T. J., Jo, H. E., Stewart, I., Glaspole, I. N., Grainge, C., Maher, T. M., Navaratnam, V., Hubbard, R., Hopkins, P. M. A., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01181-2021 · Cited by 86
Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?
Singh, V., Ulasov, I., Gupta, S., Singh, A., Roy, V. K., & Kharwar, R. K. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436180.3 · Cited by 17
Metadata
- Authors
- Inchingolo, R., Varone, F., Sgalla, G., & Richeldi, L.
- Venue
- Expert Review of Respiratory Medicine
- Publisher
- Informa UK Limited
- Published
- 2018-12-17
- Volume
- 13
- Issue
- 1
- Pages
- 39-51
- ISSN
- 1747-6348 (ISSN-L)
- 1747-6356
- OpenAlex
- W2904831059
- Cited by
- 37
- References
- 29
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1080/17476348.2019.1553620
- The paper
- Inchingolo, R., Varone, F., Sgalla, G., & Richeldi, L. (2019). Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine. https://doi.org/10.1080/17476348.2019.1553620
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.